Table 6.
Global distribution of clinical trials
| Number of continents | Total n (%) |
Recruitment status | Therapeutic purpose | |||
|---|---|---|---|---|---|---|
| Active n (%) |
Completed n (%) |
Othera n (%) |
Symptomatic n (%) |
DMTs n (%) |
||
| 1 continent | 33 (82.5%) | 7 (77.8%) | 16 (76.2%) | 10 (100%) | 24 (80%) | 9 (90%) |
| Asia | 13 (32.5%) | 0 | 8 (38.1%) | 5 (50%) | 12 | 1 (10%) |
| Europe | 4 (10%) | 2 (22.2%) | 2 (9.5%) | 0 | 3 | 1 (10%) |
| North America | 16 (40%) | 5 (55.6) | 6 (28.6%) | 5 (50%) | 9 | 7 (70%) |
| 2 continents | 5 (12.5%) | 2 (22.2%) | 3 (14.3%) | 0 | 4 (13.3%) | 1 (10%) |
| Europe and North America | 2 | 0 | 2 | 1 | 1 | |
| Europe and Oceania | 2 | 2 | 1 | 2 | ||
| North America and Latin America | 1 | 0 | 0 | 1 | ||
| 3 continents | 2 (5%) | 0 | 2 (9.5%) | 0 | 2 (6.7%) | 0 |
| Asia, Europe and North America | 1 (2.5%) | 1 (4.75%) | 1 (3.4%) | |||
| Europe, North America and Latin America | 1 (2.5%) | 1 (4.75%) | 1 (3.3%) | |||
aOther withdrawn: 3 phase 2, not yet recruiting: 2 phase 1, not recruiting: 2 phase 2, missing data: 2 phase 2, terminated 1 phase 2